Director Ra Capital Management, L.P. buys $423.8 million of Parabilis Medicines, Inc. (PBLS)
Ra Capital Management, L.P., director, bought $423.8 million of stock. WallStPal Score 62.
Ra Capital Management, L.P., director of Parabilis Medicines, Inc., bought 21,188,750 shares on the open market on June 11, 2026 at an average of $20.00 a share, for a total of $423.8 million. The purchase was reported to the SEC on Form 4 on June 15, 2026.
It is a new position: the filing shows no shares held directly before this purchase.
2 other insiders also bought at least $10,000 of PBLS within 30 days, which makes this a cluster buy.
In the 12 months up to this filing, Parabilis Medicines, Inc. insiders reported 2 open-market purchases and 0 sales.
WallStPal Score: 62 out of 100, because of a brand-new position; a large purchase; 2 other insiders also bought.
What happened next: after 1 month the stock was up 47.9% (46.9 points better than the S&P 500); after 3 months the stock was up 81.6% (77.2 points better than the S&P 500). Based on weekly prices from the week of the purchase.
Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.
Examples
Big insider purchases have made news before. In January 2016, with bank stocks falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares, about $26 million of his own money, and the purchase was widely reported as a sign of confidence.
Explain it like I'm 13
Ra Capital Management, L.P. helps run Parabilis Medicines, Inc.. Spending $423.8 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.
More: all PBLS insider trades · Ra Capital Management, L.P.'s track record